How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 30.9 | 41.0 | 41.0 | 37.8 | 37.8 | 37.8 | +7.0 |
| Healthcare | 16.6 | 18.5 | 18.5 | 25.0 | 25.0 | 25.0 | +8.4 |
| FMCG | 8.7 | 9.4 | 9.4 | 9.3 | 9.3 | 9.3 | +0.6 |
| Infrastructure | 9.6 | 10.8 | 10.8 | 7.9 | 7.9 | 7.9 | -1.7 |
| Unclassified | 5.6 | 6.9 | 6.9 | 6.8 | 6.8 | 6.8 | +1.2 |
| Chemicals | · | · | · | 0.3 | 0.3 | 0.3 | 0.0 |
| Financial Services | 3.7 | · | · | · | · | · | · |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| GLAXO | Healthcare | 9.93% | 8 | 7 | 2 | 8 | 4 | — | +31.0% |
| CONCORDBIO | Pharma | 9.66% | 8 | 4 | 2 | 5 | 3 | — | +16.2% |
| ZYDUSWELL | FMCG | 9.33% | 5 | 2 | 4 | 9 | 3 | — | +1.7% |
| ASTERDM | Healthcare | 9.25% | 6 | 2 | 9 | 4 | 2 | — | -0.6% |
| SMSPHARMA | Pharma | 7.27% | 6 | 8 | 5 | 4 | 4 | — | +3.5% |
| ALIVUS | Pharma | 7.19% | 8 | 4 | 4 | 9 | 5 | — | +34.2% |
| IPCALAB | Pharma | 5.93% | 9 | 5 | 1 | 3 | 4 | — | +14.3% |
| PFIZER | Healthcare | 5.82% | 5 | 7 | 1 | 8 | 7 | — | -2.9% |
| AUROPHARMA | Pharma | 5.14% | 8 | 3 | 10 | 6 | 7 | — | +9.9% |
| STAR | Pharma | 2.64% | 6 | 7 | 6 | 7 | 6 | — | +12.8% |
| SUMICHEM | Chemicals | 0.33% | 6 | 7 | 1 | 5 | 4 | — | +1.6% |
Performance · 3.1y
Over the last 3.1 years ₹100 in the fund grew to ₹184 (+84%), vs ₹137 for Nifty 500 (+37%) and ₹120 for Nifty 50 (+20%). Its relative-strength line ended at 152 vs Nifty 50 and 134 vs Nifty 500 — above 100, sustained outperformance.